Post on 06-Aug-2015
Congestive Heart Failure
IQ4I Research & Consultancy Pvt. Ltd.
Congestive Heart Failure
Pipeline Analysis
� REPORT DESCRIPTION
� INTRODUCTION� Causes & Symptoms
� Diagnosis
� Classification
� Compensatory mechanisms
� Unmet needs
� EPIDEMIOLOGY� Prevalence
� Incidence
� Hospitalizations
� GENETHERAPY� Pipeline
� Competitive landscape
� STEMCELL THERAPY� Pipeline
� Competitive landscape
� RNA BASED THERAPEUTICS� mi-RNA
� m-RNA
� Pipeline
� Competitive landscape
CONTENTS
� Re-admissions
� MARKET DATA� Forecasting model
� Market dynamics
� Market sizing
� Cost burden
� PIPELINE ANALYSIS� Development stage
� Modalities
� Leading players
� Innovative approaches
� Associated targets
� Competitive landscape
� DRUGS (small molecules, recombinant proteins, growth factors)
� Pipeline
� Competitive landscape
� HOT TARGETS IN RESEARCH
� MAJOR PLAYERS� Company Profiles
� Overview, Pipeline & Deals
� REFERENCES
Confidential
� “Congestive Heart Failure (CHF) Pipeline Analysis” gives comprehensiveinsight on the various drugs being developed for the treatment of CHF. Thereport covers all the drugs being developed in various development phases(Discovery to Phase 2 clinical). The pipeline focuses on disease modification andincludes pharmacologic drugs, gene therapy, stem cell therapy and RNA-basedtherapeutics, but excludes symptom relief drugs like diuretics, acute treatments,angiotensins or thrombin inhibitors etc. The report also covers some of the hottargets in research for CHF treatments.
� This report enables Pharmaceutical /Biotech companies, Academic institutes,
REPORT DESCRIPTION
� This report enables Pharmaceutical /Biotech companies, Academic institutes,Individual researchers, Investors, Medical technology companies, Serviceproviders and other associated stake holders to identify and analyze the availablelicensing/collaborative opportunities in the CHF Drug market. The report alsoprovide strategic insights on medicines that are likely to have an impact on CHFtreatment space and potentially alter standards of care in CHF in the foreseeablefuture.
� Current therapies focuses only to slow down the progression of the disease asmore number of molecules are symptom relieving drugs, hence it provides atremendous opportunity for upcoming therapies specific to CHF such as gene-based, stem cell-based and miRNA-based therapies, which reverses diseasecourse and reduce the number of cardiac events.
INTRODUCTIONINTRODUCTIONDefinition: Congestive heart failure (CHF) is a condition which is characterized by the inability
of heart muscle to pump out enough oxygen-rich blood and maintain adequate circulation of
blood in tissues of the body.
Definition: Congestive heart failure (CHF) is a condition which is characterized by the inability
of heart muscle to pump out enough oxygen-rich blood and maintain adequate circulation of
blood in tissues of the body.
CONGESTIVE HEART FAILURE (CHF)
Confidential
CHF - DIAGNOSIS
BLOOD TEST
ELECTROCHEST
CHF DIAGNOSIS
ELECTROCARDIOG
RAM
NUCLEAR IMAGING
STRESS TEST
CHEST RADIOGR
APHY
Confidential
CLINICAL CLASSIFICATION OF
HEART FAILURE
BASED ON
COURSE OF DISEASE
BASED ON
OUTPUT
BASED ON
LOCATION
BASED ON
IMPAIRED FUNCTION
CHF - CLASSIFICATION
Systolic Failure
Diastolic Failure
Acute Heart Failure
Chronic Heart
Failure
Left-sided Heart
Failure
Right-sided Heart
Failure
Low-output Heart
Failure
High-output Heart
Failure
Biventricular Heart
Failure
Confidential
North America:X MN
Europe: X MN
Asia: X MN
{MN: Million}
CHF - GLOBAL PREVALENCE
* Population living with heart failure in prominent regions across the globe, 2013 estimates
Australia: X MN
Middle East: X MN
Latin America:X MN
World: X million CHF cases
Africa & ROWX MN
Confidential
CHF - GLOBAL MARKET SIZING
Global CHF Drugs Market Global CHF Drugs Market by Region
Mar
ket
Siz
e ($
Bil
lio
n)
Fig 6 Fig 7
• The global CHF market is estimated to be $XX billion in 2013 and is expected to grow at a CAGR of XX% from
2013 to 2018 to reach $XX billion by 2018
• The market growth is attributed to technological advancements, which led to emergence of novel therapeutics,
expansion in number of heart centres, increasing incidence of cardiovascular diseases, alteration in lifestyle and
high unmet needs
Year
Mar
ket
Siz
e ($
Bil
lio
n)
Year
Confidential
CHF - PIPELINE BY DEVELOPMENT STAGE
No
: of
Mo
lecu
les
Fig 9
• Pipeline analysis reveals that there are XX molecules in various stages of pipeline (focused only on
Discovery, Pre-clinical, Phase I & Phase II candidates)
• The preclinical stage commanded the largest share with around XX molecules, followed by phase II with
around XX molecules
No
: of
Mo
lecu
les
Confidential
CHF – PIPELINE BY MODALITIES
Fig 10
Drugs
Genetherapy
Confidential
Stem cell therapy
RNA based therapy
Molecule Company Phase Target Comments
MydicarCelladon
CorpoartionPhase II b SERCA2A
Apr-2014, it has been granted grantedbreakthrough therapy designation by FDA. Goal of
this treatment is to restore the SERCA2a levels in
HF. Celladon believes that, if EMA conditions
(safety in 205-230 patients with substantial and
highly significant treatment effect and no untoward
effects are met, a PIII trial may not be required for
filing in Europe.
XX XX XX XX XX
GENE THERAPY PIPELINE
XX XX XX XX XX
XX XX XX XX XX
Confidential
Molecule Company Phase Comments
XX XX XX XX
XX XX XX XX
XX XX XX XX
XX XX XX XX
STEM CELL THERAPY PIPELINE
Confidential
RNA THERAPEUTICS PIPELINE DATA
Molecule Company Phase Comments
XX XX XX XX
XX XX XX XX
XX XX XX XX
XX XX XX XX
Confidential
CONGESTIVE HEART FAILURECONGESTIVE HEART FAILURE
DRUGS (small molecules, recombinant proteins, Growth factors)
Molecule Company Phase Target Comments
XX XX XX XX XX
XX XX XX XX XX
XX XX XX XX XX
XX XX XX XX XX
DRUGS PIPELINE
XX XX XX XX XX
Confidential
CHF KEY PLAYERS - HEADQUARTERS
Moderna therapeutics
Miragen therapeutics
Nanocor
ONO
pharmaceuticals
Celladon corporation
Juventas therapeutics
Bayer AG
GSK
Merck & Co
Confidential
Coretherapix
Nanocor therapeutics
Bioheart
Confidential
Co
Bayer is an innovative research company founded in the year 1863 and is headquartered in Germany. The
company mainly focuses on R&D activities for innovative treatment for various diseases with high unmet
medical need. With new approaches in oncology, cardiovascular diseases and gynaecological therapies Bayer
healthcare seeks to become an innovative leader. In 2013, the company revenue was accounted for $51.49
billion.
COMPANY-BAYER AG
OVERVIEW
PIPELINE
Chronic heart failureBAY-1067197
Discovery Preclinical Phase I Phase II
XXXX
XXXX
XXXX
XXXX
XXXX
XXXX
XXXX
XXXX
DISCLAIMERIQ4I strategic analysis services are limited publications containing valuable market
information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that IQ4I strategic analysis services are for our customers’ internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.
IQ4I does not endorse any vendor, product or service depicted in its research publications. IQ4I strategic analysis publications consist of the opinions of IQ4I' research and should not be construed as statements of fact. IQ4I disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
IQ4I takes no responsibility for any incorrect information supplied to us by manufacturers or users. or users.
All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of their owner.
No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission.
Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.
For information regarding permission, contact: Tel: +91 80 60500229Email: satish.birudukota@IQ4I.com
Confidential